Tonix Pharmaceuticals (TNXP) announced a collaborative research agreement under which Tonix and Makana will study Tonix’s anti-CD40L monoclonal ...

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has surged by 18.09%, which has investors questioning if this is right ...

Tonix Pharmaceuticals (NASDAQ: TNXP) , a fully integrated biopharmaceutical company, presented data at the AAPM 2025 Annual Meeting showing that its ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Tonix Pharmaceuticals (TNXP) presented data in a poster presentation at the AAPM 2025 Annual Meeting, held April 3-6, 2025, in Austin, Texas.

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 10.58%, which has investors questioning if this is right ...

TNXP READ THE FULL TNXP RESEARCH REPORT Business Update No Advisory Committee Meeting for TNX-102 SL NDA On March 24, 2025, ...

Tonix Pharmaceuticals, known for its focus on central nervous system disorders and pain management, is also advancing TNX-102 SL, a product candidate for fibromyalgia management, with a PDUFA goal ...

Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA ...

Due to the earthquake in Myanmar on March 28 and its effects on Bangkok, ONE Friday Fights 102 has been canceled. After a historic event in Japan last weekend, the world’s largest martial arts ...

Shares of Tonix Pharmaceuticals are pulling back 12.7% during Thursday's session. The stock is pulling back following a regulatory update on its experimental fibromyalgia treatment, TNX-102 SL.